{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:39:23Z","timestamp":1792852763729,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170384"],"award-info":[{"award-number":["82170384"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370383"],"award-info":[{"award-number":["82370383"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024A1515013289"],"award-info":[{"award-number":["2024A1515013289"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2024ZD00536600"],"award-info":[{"award-number":["2024ZD00536600"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2023-PT320-03"],"award-info":[{"award-number":["2023-PT320-03"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017287","name":"Special Funds for the Basic Research and Development Program in the Central Non-profit Research Institutes of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program Key Projects","doi-asserted-by":"publisher","award":["2023B03J1243"],"award-info":[{"award-number":["2023B03J1243"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program Key Projects","doi-asserted-by":"publisher","award":["2023B01J1011"],"award-info":[{"award-number":["2023B01J1011"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.arr.2025.102895","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:23:32Z","timestamp":1757517812000},"page":"102895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Use of factor XI\/XIa inhibitors in patients with atrial fibrillation: Current progress and future prospects"],"prefix":"10.1016","volume":"112","author":[{"given":"Yue","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1280-0158","authenticated-orcid":false,"given":"Wengen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2025.102895_bib1","first-page":"1311","article-title":"Left atrial appendage occlusion in patients with anticoagulation failure vs anticoagulation contraindication","volume":"17","author":"Aarnink","year":"2024","journal-title":"JACC Cardiovasc Inter."},{"key":"10.1016\/j.arr.2025.102895_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117613","article-title":"Apixaban trough concentrations in atrial fibrillation patients with reduced renal function","volume":"180","author":"Al-Aieshy","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.arr.2025.102895_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2025.0277","article-title":"Asundexian or apixaban in patients with atrial fibrillation according to prior oral anticoagulant use: a subgroup analysis of the OCEANIC-AF randomized clinical trial","author":"Alexander","year":"2025","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.arr.2025.102895_bib4","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.recesp.2024.03.008","article-title":"Late bleeding events in TAVI patients receiving vitamin k antagonists or direct oral anticoagulants","volume":"77","author":"Alperi","year":"2024","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.arr.2025.102895_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2024.100179","article-title":"Abelacimab: a leap forward in anticoagulation with FXI and FXIa inhibition","volume":"6","author":"Badreldin","year":"2024","journal-title":"Curr. Res Pharm. Drug Discov."},{"key":"10.1016\/j.arr.2025.102895_bib6","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/bcp.14732","article-title":"ONO-7684 a novel oral FXIa inhibitor: safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study","volume":"87","author":"Beale","year":"2021","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.arr.2025.102895_bib7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/FJC.0000000000000921","article-title":"Osocimab: a novel agent in preventing venous thromboembolism","volume":"76","author":"Beavers","year":"2020","journal-title":"J. Cardiovasc Pharm."},{"key":"10.1016\/j.arr.2025.102895_bib8","article-title":"Rivaroxaban versus apixaban for stroke prevention in atrial fibrillation: an instrumental variable analysis of a nationwide cohort","volume":"13","author":"Bonde","year":"2020","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"key":"10.1016\/j.arr.2025.102895_bib9","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s40262-024-01435-7","article-title":"Effect of age, sex, renal impairment and hepatic impairment on the safety, pharmacokinetics and pharmacodynamics of asundexian","volume":"63","author":"Brase","year":"2024","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.arr.2025.102895_bib10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/ehjqcco\/qcaa093","article-title":"Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs","volume":"8","author":"Burdett","year":"2022","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"10.1016\/j.arr.2025.102895_bib11","doi-asserted-by":"crossref","unstructured":"Capodanno, D., Alexander, J.H., Bahit, M.C., Eikelboom, J.W., Gibson, C.M., Goodman, S.G., Kunadian, V., Lip, G.Y.H., Lopes, R.D., Mehran, R., Mehta, S.R., Patel, M.R., Piccini, J.P., Rao, S.V., Ruff, C.T., Steg, P.G., Weitz, J.I., Angiolillo, D.J., 2025. Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism. Nature reviews. Cardiology.","DOI":"10.1038\/s41569-025-01144-z"},{"key":"10.1016\/j.arr.2025.102895_bib12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/14779072.2023.2271388","article-title":"Unresolved issues in the use of direct acting oral anticoagulants","volume":"21","author":"Chan","year":"2023","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.arr.2025.102895_bib13","article-title":"Atrial fibrillation: stroke prevention","volume":"37","author":"Chao","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.arr.2025.102895_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13895","article-title":"Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with caucasian data","volume":"17","author":"Chen","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.arr.2025.102895_bib15","article-title":"Phenotypes of south asian patients with atrial fibrillation and holistic integrated care management: cluster analysis of data from KERALA-AF registry","volume":"31","author":"Chen","year":"2024","journal-title":"Lancet Reg. Health Southeast Asia"},{"key":"10.1016\/j.arr.2025.102895_bib16","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.7326\/M21-4653","article-title":"Left atrial appendage occlusion versus oral anticoagulation in atrial fibrillation: a decision analysis","volume":"175","author":"Chew","year":"2022","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.arr.2025.102895_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70012","article-title":"Pharmacokinetics and pharmacodynamics of the factor XIa-inhibiting antibody osocimab in healthy Male east asian volunteers: results from two phase 1 studies","volume":"12","author":"Dong","year":"2024","journal-title":"Pharm. Res. Perspect."},{"key":"10.1016\/j.arr.2025.102895_bib18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.7326\/M19-2522","article-title":"Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.arr.2025.102895_bib19","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"Gailani","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.arr.2025.102895_bib20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/a-2043-0346","article-title":"Factor XI inhibitors in early clinical trials: a Meta-analysis","volume":"123","author":"Galli","year":"2023","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.arr.2025.102895_bib21","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/mco2.70058","article-title":"Disseminated intravascular coagulation: cause, molecular mechanism, diagnosis, and therapy","volume":"6","author":"Gong","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.arr.2025.102895_bib22","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.arr.2025.102895_bib23","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","article-title":"Direct oral anticoagulants versus warfarin across the spectrum of kidney function: Patient-Level network Meta-Analyses from COMBINE AF","volume":"147","author":"Harrington","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.arr.2025.102895_bib24","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1038\/s41598-025-87669-2","article-title":"Bioinformatics analysis of coagulation-related genes in lung adenocarcinoma: unveiling prognostic indicators and treatment pathways","volume":"15","author":"Huang","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2025.102895_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70058","article-title":"Absolute oral bioavailability of milvexian spray-dried dispersion formulation under fasted and fed conditions in healthy adult participants: an intravenous microtracer approach","volume":"17","author":"Jarugula","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.arr.2025.102895_bib26","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/bcp.15981","article-title":"Pharmacokinetics of asundexian with combined CYP3A and P-gp inhibitors and an inducer: target in vitro and in vivo studies","volume":"90","author":"Kanefendt","year":"2024","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.arr.2025.102895_bib27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/cpdd.1207","article-title":"Effects of tablet formulation, food, or gastric ph on the bioavailability of asundexian","volume":"12","author":"Kanefendt","year":"2023","journal-title":"Clin. Pharm. Drug Dev."},{"key":"10.1016\/j.arr.2025.102895_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ph14090886","article-title":"Lignosulfonic acid sodium is a noncompetitive inhibitor of human factor XIa","volume":"14","author":"Kar","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.arr.2025.102895_bib29","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2014810118","article-title":"Kallikrein directly interacts with and activates factor IX, resulting in thrombin generation and fibrin formation independent of factor XI","volume":"118","author":"Kearney","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2025.102895_bib30","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1055\/s-0043-57034","article-title":"Plasma kallikrein as a forgotten clotting factor","volume":"50","author":"Kearney","year":"2024","journal-title":"Semin Thromb. Hemost."},{"key":"10.1016\/j.arr.2025.102895_bib31","doi-asserted-by":"crossref","first-page":"37340","DOI":"10.1074\/jbc.M003909200","article-title":"SERPIN regulation of factor XIa. The novel observation that protease nexin 1 in the presence of heparin is a more potent inhibitor of factor XIa than C1 inhibitor","volume":"275","author":"Knauer","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2025.102895_bib32","article-title":"Latent class analysis for the identification of phenotypes associated with increased risk in atrial fibrillation patients. The COOL-AF registry","author":"Krittayaphong","year":"2025","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.arr.2025.102895_bib33","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.arr.2025.102895_bib34","article-title":"Atrial fibrillation: epidemiology, screening and digital health","volume":"37","author":"Linz","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.arr.2025.102895_bib35","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1055\/s-0043-1764469","article-title":"Substrates, cofactors, and cellular targets of coagulation factor XIa","volume":"50","author":"Lira","year":"2024","journal-title":"Semin Thromb. Hemost."},{"key":"10.1016\/j.arr.2025.102895_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13784","article-title":"Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and caucasian volunteers","volume":"17","author":"Liu","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.arr.2025.102895_bib37","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2147\/DDDT.S488414","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of milvexian in healthy Chinese adults","volume":"19","author":"Luo","year":"2025","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.arr.2025.102895_bib38","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/13543784.2024.2391837","article-title":"The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects","volume":"33","author":"Ma","year":"2024","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.arr.2025.102895_bib39","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jamaneurol.2024.2882","article-title":"Left atrial appendage occlusion vs standard of care after ischemic stroke despite anticoagulation","volume":"81","author":"Maarse","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2025.102895_bib40","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.hrthm.2024.01.018","article-title":"Lower rate of major bleeding in very high risk patients undergoing left atrial appendage occlusion: a propensity score-matched comparison with direct oral anticoagulant","volume":"21","author":"Magnocavallo","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.arr.2025.102895_bib41","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood.2023020719","article-title":"Biology of factor XI","volume":"143","author":"Moellmer","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.arr.2025.102895_bib42","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.124.002203","article-title":"Mechanisms and management of thrombosis in cancer: focus on gastrointestinal malignancies","volume":"392","author":"Monegatti","year":"2025","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.arr.2025.102895_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.hrthm.2025.05.040","article-title":"East asian immigration and direct oral anticoagulant dosing for atrial fibrillation: a population-based cohort study","author":"Nakajima","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.arr.2025.102895_bib44","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jacc.2025.05.060","article-title":"Outcomes in older patients after switching to a newer anticoagulant or remaining on warfarin: the COMBINE-AF substudy","volume":"86","author":"Nicolau","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.arr.2025.102895_bib45","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1093\/cvr\/cvac196","article-title":"Factor XIa inhibition in atrial fibrillation: insights and knowledge gaps emerging from the PACIFIC-AF trial","volume":"119","author":"Ninni","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.arr.2025.102895_bib46","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev-pharmtox-032823-122811","article-title":"Oral anticoagulants beyond warfarin","volume":"64","author":"Olie","year":"2024","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"10.1016\/j.arr.2025.102895_bib47","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0004-2022","article-title":"Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer","volume":"31","author":"Otten","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.arr.2025.102895_bib48","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.medj.2024.10.001","article-title":"The impact of OCEANIC-AF and the future of factor XIa inhibitors","volume":"5","author":"Palaiodimou","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.arr.2025.102895_bib49","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1016\/j.jtha.2024.07.011","article-title":"Evaluating the safety and effectiveness of direct oral anticoagulants compared with warfarin in very elderly patients with atrial fibrillation with and without low bodyweight","volume":"22","author":"Patil","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.arr.2025.102895_bib50","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s40262-022-01150-1","article-title":"Single-Dose pharmacokinetics of milvexian in participants with normal renal function and participants with moderate or severe renal impairment","volume":"61","author":"Perera","year":"2022","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.arr.2025.102895_bib51","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1038\/s41598-022-08768-y","article-title":"Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants","volume":"12","author":"Perera","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2025.102895_bib52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40119-022-00266-6","article-title":"Effects of itraconazole and diltiazem on the pharmacokinetics and pharmacodynamics of milvexian, a factor XIa inhibitor","volume":"11","author":"Perera","year":"2022","journal-title":"Cardiol. Ther."},{"key":"10.1016\/j.arr.2025.102895_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25936-2","article-title":"Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor","volume":"12","author":"Perera","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2025.102895_bib54","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.arr.2025.102895_bib55","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2025.102895_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2025.102895_bib57","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13318-023-00838-4","article-title":"Metabolism and disposition of the novel oral factor XIa inhibitor asundexian in rats and in humans","volume":"48","author":"Piel","year":"2023","journal-title":"Eur. J. Drug Metab. Pharm."},{"key":"10.1016\/j.arr.2025.102895_bib58","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1182\/bloodadvances.2020002456","article-title":"The evolution of factor XI and the kallikrein-kinin system","volume":"4","author":"Ponczek","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.arr.2025.102895_bib59","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.4049\/jimmunol.2000398","article-title":"Cross-Talk between the complement pathway and the contact activation system of coagulation: activated factor XI neutralizes complement factor h","volume":"206","author":"Puy","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.arr.2025.102895_bib60","doi-asserted-by":"crossref","first-page":"12203","DOI":"10.1021\/acs.jmedchem.3c00795","article-title":"Design and preclinical characterization program toward asundexian (BAY 2433334), an oral factor XIa inhibitor for the prevention and treatment of thromboembolic disorders","volume":"66","author":"Roehrig","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.arr.2025.102895_bib61","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1055\/s-0042-1756355","article-title":"Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III","volume":"122","author":"Romiti","year":"2022","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.arr.2025.102895_bib62","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2025.102895_bib63","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/09537104.2018.1428738","article-title":"Improving the understanding of plasma kallikrein contribution to arterial thrombus formation using two plant protease inhibitors","volume":"30","author":"Salu","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.arr.2025.102895_bib64","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.arr.2025.102895_bib65","article-title":"Factor XIII-A transglutaminase contributes to neutrophil extracellular trap (NET)-mediated Fibrin(ogen) network formation and crosslinking","author":"Soltani","year":"2025","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.arr.2025.102895_bib66","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ekir.2024.10.007","article-title":"A systematic review of safety and efficacy of factor XI\/XIa inhibitors in patients with ESKD on hemodialysis","volume":"10","author":"Steiner","year":"2025","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.arr.2025.102895_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.151494","article-title":"A mini review on the regulation of coagulation homeostasis through interfering with vitamin K-dependent coagulation\/anticoagulation factors","volume":"753","author":"Tong","year":"2025","journal-title":"Biochem Biophys. Res. Commun."},{"key":"10.1016\/j.arr.2025.102895_bib68","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2025.102895_bib69","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/eurheartj\/ehae776","article-title":"Interplay between platelets and coagulation: from protective haemostasis to pathological arterial thrombosis","volume":"46","author":"Vilahur","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.arr.2025.102895_bib70","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1124\/jpet.116.238600","article-title":"Inhibition of factor XIa reduces the frequency of cerebral microembolic signals derived from carotid arterial thrombosis in rabbits","volume":"360","author":"Wang","year":"2017","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.arr.2025.102895_bib71","article-title":"Antithrombotic effects of the novel Small-Molecule factor XIa inhibitor milvexian in a rabbit arteriovenous shunt model of venous thrombosis","author":"Wang","year":"2023","journal-title":"TH Open 7"},{"key":"10.1016\/j.arr.2025.102895_bib72","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1111\/j.1538-7836.2006.02093.x","article-title":"Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice","volume":"4","author":"Wang","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.arr.2025.102895_bib73","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.kint.2024.02.024","article-title":"A phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis","volume":"106","author":"Winkelmayer","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.arr.2025.102895_bib74","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"Wong","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.arr.2025.102895_bib75","article-title":"Factor XIa inhibitors as a novel anticoagulation target: recent clinical research advances","volume":"16","author":"Xia","year":"2023","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.arr.2025.102895_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/bcp.70043","article-title":"Pharmacokinetics, pharmacodynamics and safety profile of SKB336, a selective inhibitor of coagulation factor XI\/XIa in healthy subjects","author":"Xiang","year":"2025","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.arr.2025.102895_bib77","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40261-023-01281-8","article-title":"The safety, pharmacokinetics, and pharmacodynamics of SHR2285, an oral small molecule factor XIa inhibitor, in healthy Chinese volunteers","volume":"43","author":"Xu","year":"2023","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.arr.2025.102895_bib78","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1021\/bi802298r","article-title":"Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor","volume":"48","author":"Yang","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.arr.2025.102895_bib79","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.arr.2025.102895_bib80","doi-asserted-by":"crossref","first-page":"16091","DOI":"10.1021\/acs.analchem.4c04369","article-title":"Development of an ultrasensitive competitive Double-Enzyme cascade fluorescence signal amplification method for factor XIa inhibitor screening","volume":"96","author":"Zhan","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.arr.2025.102895_bib81","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2147\/JIR.S504184","article-title":"The mechanisms of sepsis induced coagulation dysfunction and its treatment","volume":"18","author":"Zhu","year":"2025","journal-title":"J. Inflamm. Res."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163725002417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163725002417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:34:01Z","timestamp":1780126441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163725002417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":81,"alternative-id":["S1568163725002417"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2025.102895","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of factor XI\/XIa inhibitors in patients with atrial fibrillation: Current progress and future prospects","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2025.102895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102895"}}